Sindhu Carmen Sivakumaren

Harvard Medical School/Dana-Farber Cancer Institute, Boston, MA, United States 
Kinase signaling inhibition in cancer therapeutics
"Sindhu Sivakumaren"
Mean distance: (not calculated yet)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Manz TD, Sivakumaren SC, Ferguson FM, et al. (2020) Discovery and Structure-Activity Relationship Study of (Z)-5-Methylenethiazolidin-4-one Derivatives as Potent and Selective Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors. Journal of Medicinal Chemistry
Manz TD, Sivakumaren SC, Yasgar A, et al. (2020) Structure-Activity Relationship Study of Covalent Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors. Acs Medicinal Chemistry Letters. 11: 346-352
Sivakumaren SC, Shim H, Zhang T, et al. (2020) Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors. Cell Chemical Biology
Chopra SS, Jenney A, Palmer A, et al. (2019) Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells. Cell Systems
Chopra SS, Jenney A, Palmer A, et al. (2019) Abstract B103: Torin2 and related analogs exploit replicative and checkpoint vulnerabilities to induce death of triple-negative breast cancer cells Molecular Cancer Therapeutics. 18
Browne CM, Jiang B, Ficarro SB, et al. (2018) A Chemoproteomic Strategy for Direct and Proteome-wide Covalent Inhibitor Target-site Identification. Journal of the American Chemical Society
See more...